Rice Hall James & Associates LLC raised its stake in shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) by 24.3% during the second quarter, Holdings Channel reports. The fund owned 1,666,934 shares of the biopharmaceutical company’s stock after buying an additional 326,285 shares during the period. Rice Hall James & Associates LLC’s holdings in Keryx Biopharmaceuticals were worth $12,052,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. American International Group Inc. raised its stake in shares of Keryx Biopharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 48,622 shares of the biopharmaceutical company’s stock worth $300,000 after buying an additional 3,220 shares in the last quarter. Stifel Financial Corp raised its stake in shares of Keryx Biopharmaceuticals by 11.5% in the first quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 3,478 shares in the last quarter. Shufro Rose & Co. LLC raised its stake in shares of Keryx Biopharmaceuticals by 0.7% in the first quarter. Shufro Rose & Co. LLC now owns 73,200 shares of the biopharmaceutical company’s stock worth $451,000 after buying an additional 500 shares in the last quarter. Iridian Asset Management LLC CT raised its stake in shares of Keryx Biopharmaceuticals by 16.0% in the first quarter. Iridian Asset Management LLC CT now owns 265,110 shares of the biopharmaceutical company’s stock worth $1,633,000 after buying an additional 36,540 shares in the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Keryx Biopharmaceuticals by 60.1% in the first quarter. Parametric Portfolio Associates LLC now owns 192,982 shares of the biopharmaceutical company’s stock worth $1,189,000 after buying an additional 72,436 shares in the last quarter. 57.06% of the stock is currently owned by institutional investors.

Keryx Biopharmaceuticals, Inc. (NASDAQ KERX) opened at 6.42 on Friday. The stock’s market cap is $762.38 million. Keryx Biopharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.38. The company’s 50-day moving average price is $7.24 and its 200-day moving average price is $6.15.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.60. The company had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.51 million. Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. Keryx Biopharmaceuticals’s quarterly revenue was up 62.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.42) EPS. Equities analysts forecast that Keryx Biopharmaceuticals, Inc. will post ($1.23) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Shares Bought by Rice Hall James & Associates LLC” was published by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/12/keryx-biopharmaceuticals-inc-nasdaqkerx-shares-bought-by-rice-hall-james-associates-llc.html.

A number of analysts have recently issued reports on the company. Maxim Group reaffirmed a “buy” rating and issued a $7.00 price target on shares of Keryx Biopharmaceuticals in a research note on Monday, May 1st. ValuEngine raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. BidaskClub lowered Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Zacks Investment Research lowered Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 price target (up from $4.00) on shares of Keryx Biopharmaceuticals in a research note on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $7.48.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX).

Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.